Vertex Pharmaceuticals (VRTX) closed at $492.47 in the latest trading session, marking a +0.01% move from the prior day.

Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller ...

The Nasdaq Composite has been a goldmine for investors, powered by technology, artificial intelligence, and visionary companies that drive the future. In 2024, ...

Palantir Technologies Inc is expanding its FedStart platform through a new partnership with Google Public Sector, enabling ...

Calidi Biotherapeutics (NYSE American: CLDI) announced the appointment of Eric Poma, Ph.D., as Chief Executive Officer and member of its Board of Di ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

The new solution will supply marketers with data-driven insights to make smarter business decisions that optimize marketing spend and drive revenue growth.Atlanta, April 23, 2025 (GLOBE NEWSWIRE) -- ...

The biopharmaceutical industry saw a strong start to 2025, despite ongoing uncertainty around the potential impact of US ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

When the stock market is highly volatile, many investors flock to assets that offer stability but dismal growth prospects.

Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth ...

Barclays downgraded Texas Instruments (NASDAQ:TXN) to "Underweight" from "Equal Weight" and cut its price target to $125 amid growing risks tied to U.S.-China trade tensions, rising production costs, ...